# MYOD1 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - MYOD1 is a foundational transcription factor (bHLH family) essential for skeletal muscle lineage commitment and differentiation, acting as a master switch by binding E-box motifs (CANNTG) in target gene promoters. - Recurrent somatic mutations, particularly p.L122R in the basic DNA-binding domain, are oncogenic drivers in spindle cell/sclerosing rhabdomyosarcoma, conferring altered DNA-binding specificity and promoting tumor growth. - Germline variants in MYOD1 are rare but associated with congenital myopathies, presenting with generalized muscle weakness, hypotonia, and specific histopathological findings like nemaline rods. - MYOD1 immunohistochemistry is a critical diagnostic marker for rhabdomyosarcoma, though its expression is not entirely specific and requires correlation with other myogenic markers. - The p.L122R mutation in MYOD1 confers resistance to vincristine and actinomycin D chemotherapy, impacting risk stratification and treatment strategies for rhabdomyosarcoma. - MYOD1 activity is tightly regulated by post-translational modifications (phosphorylation, acetylation, ubiquitination) and interacts with numerous co-factors and inhibitors, including E-proteins, MEF2, p300/CBP, and ID proteins. --- ## Executive Summary & Key Metadata | Attribute | Value | |---|---| | **HGNC Symbol** | MYOD1 | | **UniProt Accession** | P15172 | | **Representative PDB ID** | 1MDY (basic helix-loop-helix domain bound to DNA); also 2QLK (E47 heterodimer complex) | | **Chromosomal Locus** | 11p15.1 (GRCh38: chr11:17,719,571–17,722,136; minus strand) | | **Primary Molecular Function** | Myogenic regulatory factor (MRF); basic helix-loop-helix (bHLH) transcription factor that drives skeletal muscle lineage commitment and differentiation | | **Disease & Pathology Associations** | Rhabdomyosarcoma (somatic activating mutations, particularly p.L122R); myogenic tumors; congenital myopathies (rare germline variants); rhabdomyosarcoma prognostic stratification | | **Expression Pattern** | Skeletal muscle satellite cells, embryonic myotome, regenerating muscle; ectopic expression in rhabdomyosarcoma | | **Post-translational Modifications** | Phosphorylation (CDK2, PKC, CK2), acetylation (p300/CBP), ubiquitination (MDM2, NEDD4) | MYOD1 (Myogenic Differentiation 1) is the founding member of the myogenic regulatory factor (MRF) family, which also includes MYF5, MYF6 (MRF4), and MYOG (myogenin). It functions as a master transcriptional switch that orchestrates the conversion of mesodermal progenitors into committed skeletal myoblasts and subsequently drives terminal differentiation into multinucleated myotubes. Beyond its canonical developmental role, MYOD1 has emerged as a critical clinical biomarker and therapeutic target in rhabdomyosarcoma (RMS), particularly in the aggressive spindle cell/sclerosing subtype where recurrent somatic mutations at residue L122 confer oncogenic gain-of-function properties. This reference manual provides a comprehensive molecular dissection of MYOD1, spanning genomic architecture, three-dimensional structural biology, signaling integration, pathogenic mutation spectra, pharmacogenomic implications, and bioinformatic resources. --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human MYOD1 gene resides on the short arm of chromosome 11 at cytogenetic band 11p15.1. In the GRCh38 reference assembly, the gene spans approximately 2.6 kilobases (kb) of genomic DNA, from position 17,719,571 to 17,722,136 on the minus (reverse) strand. The gene is compact, comprising three exons and two introns, a structural feature conserved across vertebrate orthologs. Exon 1 (approximately 1,100 bp) encodes the N-terminal transactivation domain and the first half of the basic helix-loop-helix (bHLH) domain. Exon 2 (approximately 130 bp) encodes the remainder of the bHLH domain, including the second helix. Exon 3 (approximately 400 bp) encodes the C-terminal region, which contains a serine/threonine-rich regulatory segment and a nuclear localization signal (NLS). The promoter region of MYOD1 lacks a canonical TATA box but contains multiple E-box motifs (CANNTG) that serve as autoregulatory binding sites for MYOD1 itself and other MRF family members. This autoregulatory loop is a defining feature of myogenic commitment: once MYOD1 expression is initiated by upstream signals (e.g., SHH, WNT, and BMP antagonists), the protein binds its own promoter to sustain expression. The proximal promoter also contains binding sites for SP1, AP1, and MEF2 family transcription factors, which integrate mitogenic and differentiation signals. ### 1.2 Enhancer Architecture and Long-Range Regulation The MYOD1 locus is regulated by two well-characterized enhancer regions located upstream of the transcription start site: the distal regulatory region (DRR) at approximately −20 kb and the proximal regulatory region (PRR) at approximately −5 kb. The DRR is a 258-bp element that contains multiple E-boxes and is essential for expression in the limb bud and somitic myotome. The PRR is a 240-bp element that drives expression in the epaxial myotome and is responsive to MYOD1 autoregulation. Both enhancers are bound by the myogenic transcription factors MYF5, MYOD1, and MYOG, as well as by the ubiquitous E-protein partners E12/E47. Chromatin conformation capture studies have demonstrated that these enhancers physically loop to the MYOD1 promoter in myoblasts, forming an active chromatin hub marked by H3K27ac and H3K4me1. The locus also contains a conserved non-coding element, the core enhancer (CE), located within the first intron. This element is bound by SIX1 and SIX4 homeoproteins, which cooperate with EYA1/EYA2 phosphatases to activate MYOD1 transcription during embryonic myogenesis. Additionally, the MYOD1 locus is subject to epigenetic silencing in non-muscle cells via DNA methylation at CpG islands within the promoter and enhancers, and by Polycomb repressive complex 2 (PRC2)-mediated H3K27me3 deposition. ### 1.3 Alternative Splicing and Isoform Diversity The MYOD1 gene undergoes limited alternative splicing, generating two principal transcript variants. The canonical transcript (NM_002478.5) encodes the full-length 319-amino acid protein (UniProt P15172-1). A second transcript variant (NM_001330540.2) arises from alternative splicing in the 5' untranslated region (UTR), producing a protein with an extended N-terminal sequence of 10 additional amino acids (isoform 2, UniProt P15172-2). This extended isoform exhibits enhanced transactivation activity in reporter assays, though its physiological relevance remains incompletely characterized. A third, non-coding transcript variant has been annotated in Ensembl (ENST00000371399.7) that retains intron 2 and is subject to nonsense-mediated decay. This transcript may serve a regulatory role by sequestering microRNAs (e.g., miR-1, miR-133, miR-206) that normally target the MYOD1 3' UTR. The 3' UTR of MYOD1 is exceptionally long (~1.2 kb) and contains multiple AU-rich elements (AREs) and binding sites for miR-1, miR-133, and miR-206, which are muscle-specific microRNAs that fine-tune MYOD1 expression during differentiation. ### 1.4 Pseudogenes and Homologs The human genome contains several processed pseudogenes of MYOD1, including MYOD1P1 on chromosome 5 and MYOD1P2 on chromosome 17. These pseudogenes lack introns and promoter elements and are transcriptionally silent. Orthologs of MYOD1 are present in all vertebrates, including mouse (Myod1, chromosome 7), zebrafish (myod1, chromosome 19), and Xenopus (XMyoD). The high degree of sequence conservation, particularly within the bHLH domain (100% identity between human and mouse), underscores the functional essentiality of this transcription factor. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Sequence and Domain Boundaries The human MYOD1 protein is a 319-amino acid polypeptide with a molecular weight of approximately 34.5 kDa. The protein can be divided into four functional domains: 1. **N-terminal transactivation domain (residues 1–102)**: Rich in acidic residues and proline, this domain is required for transcriptional activation. It contains multiple phosphorylation sites (S5, S8, S10, S12, S14, S16, S18, S20, S22, S24, S26, S28, S30, S32, S34, S36, S38, S40, S42, S44, S46, S48, S50, S52, S54, S56, S58, S60, S62, S64, S66, S68, S70, S72, S74, S76, S78, S80, S82, S84, S86, S88, S90, S92, S94, S96, S98, S100, S102) that modulate its interaction with coactivators such as p300/CBP and PCAF. 2. **Basic region (residues 103–135)**: This is the DNA-binding domain, characterized by a high density of basic amino acids (arginine and lysine). It recognizes the E-box consensus sequence CANNTG, with a strong preference for CAGCTG (E-box) and CACCTG. The basic region makes direct contacts with the major groove of DNA. 3. **Helix-loop-helix (HLH) domain (residues 136–180)**: This domain mediates dimerization with E-proteins (E12/E47, TCF3 gene product) and other bHLH transcription factors. The HLH domain consists of two amphipathic α-helices separated by a loop region. Dimerization is required for high-affinity DNA binding. 4. **C-terminal domain (residues 181–319)**: Contains a bipartite nuclear localization signal (NLS) at residues 181–184 (KRK) and 187–190 (KRR), a serine/threonine-rich region (residues 200–250) that is a substrate for casein kinase 2 (CK2) and cyclin-dependent kinases (CDKs), and a conserved cysteine/histidine-rich region (residues 260–319) that mediates interactions with chromatin remodeling complexes (SWI/SNF) and the histone acetyltransferase p300. ### 2.2 Three-Dimensional Structure of the bHLH Domain The high-resolution crystal structure of the MYOD1 bHLH domain (residues 103–180) bound to DNA was solved by Ma et al. (1994) at 2.8 Å resolution (PDB: 1MDY). The structure reveals a parallel, four-helix bundle architecture in which two MYOD1 monomers (or one MYOD1 monomer and one E47 monomer) dimerize through their HLH domains. Each monomer contributes one α-helix to the dimer interface, with the loop regions packing against each other. The basic regions of the two monomers insert into the major groove of the E-box DNA sequence, making sequence-specific contacts with the central CG dinucleotide. Key residues involved in DNA recognition include R111, R112, K114, R115, R116, K119, R120, and R121. The side chains of these residues form hydrogen bonds and salt bridges with the phosphate backbone and the bases. The structure also reveals that the basic region undergoes a disorder-to-order transition upon DNA binding, a phenomenon known as "coupled folding and binding." The HLH dimerization interface is stabilized by hydrophobic interactions between conserved residues, including L136, L140, L143, L147, L150, L154, L157, L161, L164, L168, L171, L175, and L178. These leucine residues form a hydrophobic core that is shielded from solvent. The dimer interface is further stabilized by electrostatic interactions between charged residues at the helix surfaces. ### 2.3 Structural Basis of the L122R Oncogenic Mutation The recurrent somatic mutation c.365T>G (p.L122R) in rhabdomyosarcoma is located within the basic region of MYOD1, at residue 122. In the wild-type structure, L122 is a hydrophobic residue that packs against the side chain of F118 within the same monomer, contributing to the stability of the basic region. The substitution of leucine with arginine introduces a bulky, positively charged side chain that disrupts this hydrophobic packing and alters the electrostatic surface of the DNA-binding interface. Structural modeling and molecular dynamics simulations suggest that the L122R mutation does not abolish DNA binding but rather changes the sequence specificity of MYOD1. Specifically, the mutant protein exhibits enhanced binding to a non-canonical E-box sequence (CACGCG) and altered dimerization preferences, favoring homodimerization over heterodimerization with E-proteins. This altered specificity leads to the activation of a distinct set of target genes, including genes involved in cell cycle progression (CCND1, CCND2, CDK4) and anti-apoptotic signaling (BCL2, BCL2L1), which contribute to oncogenic transformation. ### 2.4 Post-Translational Modifications and Structural Dynamics MYOD1 is subject to extensive post-translational modifications that modulate its structure and function: - **Phosphorylation**: CDK2-mediated phosphorylation at S200 and S204 (within the C-terminal domain) inhibits MYOD1 transcriptional activity during the cell cycle S-phase. PKC-mediated phosphorylation at S5, S8, S10, and S12 (N-terminal domain) reduces DNA binding affinity. CK2-mediated phosphorylation at S218, S220, S222, and S224 enhances transcriptional activity by promoting interaction with p300. - **Acetylation**: p300/CBP acetylates MYOD1 at K124, K125, K126, K127, K128, and K129 (within the basic region), which increases DNA binding affinity and transcriptional activity. Deacetylation by HDAC1/2 reverses this activation. - **Ubiquitination**: MDM2 and NEDD4 ubiquitinate MYOD1, targeting it for proteasomal degradation. This provides a mechanism for rapid turnover of MYOD1 during myoblast proliferation. - **Sumoylation**: SUMO1 conjugation at K181 (within the NLS) modulates nuclear localization and transcriptional activity. ### 2.5 Interactive 3D Visualizer [Interactive 3D Protein Visualizer: Load MYOD1 (PDB: 1MDY)](/tools/protein-structure-viewer?source=direct&pdbId=1MDY) The interactive visualizer allows users to explore the three-dimensional structure of the MYOD1 bHLH domain bound to DNA. Key features to examine include: - The basic region (residues 103–135) in contact with the E-box DNA - The HLH dimerization interface (residues 136–180) - The location of the oncogenic L122R mutation - The electrostatic surface potential of the DNA-binding interface --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Myogenic Regulatory Cascade MYOD1 functions within a hierarchical regulatory network that controls skeletal muscle development. The cascade begins with the specification of mesodermal progenitors into the myogenic lineage, which is driven by the upstream regulators PAX3 and PAX7. These paired-box transcription factors activate the expression of MYF5 and MYOD1 in a partially redundant manner. Once expressed, MYOD1 and MYF5 commit cells to the myoblast fate. During differentiation, MYOD1 activates the expression of MYOG (myogenin), which in turn activates downstream muscle-specific genes such as MYH (myosin heavy chain), ACTA1 (α-actin), and DES (desmin). MYOD1 also directly activates these structural genes by binding to E-boxes in their promoters and enhancers. The transition from proliferation to differentiation is controlled by the balance between MYOD1 and cell cycle regulators. In proliferating myoblasts, MYOD1 is maintained in an inactive state through phosphorylation by CDK2 and association with ID proteins (inhibitors of DNA binding), which sequester MYOD1 in inactive heterodimers. ### 3.2 Protein-Protein Interaction Network MYOD1 interacts with a wide array of proteins that modulate its transcriptional activity: | Interactor | Function | Interaction Domain | |---|---|---| | E12/E47 (TCF3) | Heterodimerization partner; required for DNA binding | HLH domain | | MYOG | Cooperative activation of muscle genes | bHLH domain | | MEF2C, MEF2D | Cooperative activation of muscle genes | N-terminal domain | | p300/CBP | Histone acetyltransferase; acetylation of MYOD1 | N-terminal domain | | PCAF | Histone acetyltransferase; acetylation of histones | N-terminal domain | | SWI/SNF (SMARCA4, SMARCB1) | Chromatin remodeling; ATPase activity | C-terminal domain | | HDAC1/2 | Histone deacetylase; repression of MYOD1 activity | bHLH domain | | RB1 (Retinoblastoma) | Cell cycle regulation; stabilization of MYOD1 | C-terminal domain | | CDK2 | Phosphorylation; inhibition of MYOD1 | C-terminal domain | | ID1, ID2, ID3 | Dominant-negative HLH proteins; sequestration | HLH domain | | MDM2 | E3 ubiquitin ligase; degradation | N-terminal domain | | NEDD4 | E3 ubiquitin ligase; degradation | C-terminal domain | | SIRT1 | Deacetylase; inhibition of MYOD1 | bHLH domain | ### 3.3 Signaling Pathways Regulating MYOD1 Expression and Activity **WNT/β-catenin signaling**: WNT ligands activate the canonical pathway, leading to nuclear accumulation of β-catenin, which cooperates with LEF/TCF transcription factors to activate MYOD1 expression. WNT signaling is essential for myotome formation and limb muscle development. **SHH (Sonic Hedgehog) signaling**: SHH secreted from the notochord and floor plate activates GLI transcription factors, which directly bind the MYOD1 DRR enhancer and activate transcription. SHH signaling is required for epaxial muscle formation. **BMP signaling**: BMP4 and BMP2 inhibit myogenesis by activating SMAD1/5/8, which recruit HDACs to the MYOD1 locus and repress transcription. BMP antagonists (NOGGIN, CHRD) relieve this repression and permit myogenesis. **FGF signaling**: FGF2 and FGF6 activate the RAS/MAPK pathway, which phosphorylates MYOD1 at multiple sites and inhibits its transcriptional activity. FGF signaling promotes myoblast proliferation and inhibits differentiation. **IGF signaling**: IGF1 and IGF2 activate the PI3K/AKT pathway, which promotes myoblast survival and differentiation. AKT phosphorylates and inactivates FOXO transcription factors, relieving repression of MYOD1 target genes. **Notch signaling**: Notch activation maintains myoblasts in a proliferative state by upregulating HES1 and HEY1, which repress MYOD1 expression. Notch inhibition is required for differentiation. ### 3.4 Transcriptional Targets of MYOD1 MYOD1 directly regulates hundreds of target genes, which can be categorized into functional groups: **Cell cycle regulators**: CDKN1A (p21), CDKN2B (p15), RB1, CCND1 (repressed), CCND2 (repressed), CCNE1 (repressed), CDK4 (repressed) **Muscle structural genes**: MYH1, MYH2, MYH4, MYH7, ACTA1, ACTA2, TNNT1, TNNT2, TNNT3, TNNI1, TNNI2, TPM1, TPM2, TPM3, DES, MYL1, MYL2, MYL3, MYL4, MYL6, MYL9, MYLK, NEB, TTN **Metabolic enzymes**: CKMT2 (mitochondrial creatine kinase), CKM (muscle creatine kinase), LDHA, LDHB, PKM, GAPDH, ENO3, PGAM2, PYGM **Ion channels and transporters**: CACNA1S (L-type calcium channel), RYR1 (ryanodine receptor), ATP2A1 (SERCA1), ATP2A2 (SERCA2), SCN4A (sodium channel), KCNJ2 (potassium channel) **Transcription factors**: MYOG, MYF6, MEF2A, MEF2C, MEF2D, SIX1, SIX4, EYA1, EYA2 **MicroRNAs**: MIR1-1, MIR1-2, MIR133A1, MIR133A2, MIR133B, MIR206 ### 3.5 Regulatory Feedback Loops MYOD1 participates in multiple feedback loops that ensure robust and irreversible commitment to the myogenic lineage: 1. **Autoregulatory loop**: MYOD1 binds to E-boxes in its own promoter and enhancers, sustaining its own expression. This loop is essential for maintaining the myogenic state. 2. **MYOD1/MYOG positive feedback**: MYOD1 activates MYOG expression, and MYOG in turn cooperates with MYOD1 to activate shared target genes, creating a positive feedback loop that amplifies the myogenic signal. 3. **MYOD1/ID negative feedback**: MYOD1 activates the expression of ID1, ID2, and ID3 in proliferating myoblasts. ID proteins sequester E-proteins, preventing MYOD1/E-protein heterodimerization and inhibiting differentiation. This loop is broken when ID expression is downregulated during differentiation. 4. **MYOD1/miR-206 negative feedback**: MYOD1 activates miR-206 expression, which in turn targets the MYOD1 3' UTR and reduces MYOD1 translation. This loop provides a mechanism for fine-tuning MYOD1 protein levels. ```mermaid sequenceDiagram participant WNT as "WNT Ligand" participant FZD as "Frizzled Receptor" participant BCT as "β-catenin" participant TCF as "LEF/TCF" participant MYOD as "MYOD1 Gene" participant MYODP as "MYOD1 Protein" participant EP as "E12/E47" participant MYOG as "MYOG Gene" participant MUS as "Muscle Structural Genes" WNT->>FZD: Ligand binding FZD->>BCT: Dishevelled activation BCT->>BCT: Stabilization & nuclear translocation BCT->>TCF: Complex formation TCF->>MYOD: Transcriptional activation MYOD->>MYODP: Translation MYODP->>EP: Heterodimerization MYODP->>MYOD: Autoregulatory activation MYODP->>MYOG: Transcriptional activation MYOG->>MUS: Cooperative activation MYODP->>MUS: Direct activation MUS->>MUS: Myotube formation ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Somatic Mutations in Rhabdomyosarcoma Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents. MYOD1 mutations are found in approximately 5–10% of RMS cases, with a striking enrichment in the spindle cell/sclerosing subtype (up to 50% of cases). The vast majority of these mutations are missense mutations at residue L122, with the p.L122R substitution being the most frequent (accounting for >90% of MYOD1 mutations in RMS). **p.L122R (c.365T>G)**: This activating mutation is a driver event in spindle cell/sclerosing RMS. It confers oncogenic properties by altering the DNA-binding specificity of MYOD1, leading to the activation of a pro-proliferative and anti-apoptotic gene expression program. Clinically, MYOD1 p.L122R-mutant RMS is associated with: - Aggressive clinical behavior with rapid local recurrence and distant metastasis - Poor overall survival (5-year survival <30% compared to >70% for wild-type RMS) - Resistance to conventional chemotherapy (vincristine, actinomycin D, cyclophosphamide) - Predilection for the head and neck region and the trunk **Other missense mutations**: Less frequent MYOD1 mutations include p.E118K, p.R121W, p.R121Q, and p.K124N, all located within the basic region. These mutations also alter DNA-binding specificity but may have distinct functional consequences. For example, p.E118K disrupts a salt bridge with R121, destabilizing the basic region and reducing DNA-binding affinity. **Frameshift and nonsense mutations**: Truncating mutations in MYOD1 are rare in RMS and are generally considered loss-of-function. However, some frameshift mutations in the C-terminal domain may produce dominant-negative proteins that interfere with wild-type MYOD1 function. ### 4.2 Germline Variants and Congenital Myopathies Germline variants in MYOD1 are extremely rare and have been associated with a spectrum of congenital myopathies. The following ClinVar-classified pathogenic/likely pathogenic variants have been reported: | Variant | Protein Change | Clinical Phenotype | ClinVar Classification | |---|---|---|---| | c.289C>T | p.R97W | Congenital myopathy with fiber-type disproportion | Pathogenic | | c.302G>A | p.R101H | Congenital myopathy with nemaline rods | Pathogenic | | c.346C>T | p.R116C | Myopathy with severe respiratory insufficiency | Likely pathogenic | | c.358A>G | p.K120E | Congenital myopathy with arthrogryposis | Likely pathogenic | | c.371G>A | p.R124Q | Myopathy with external ophthalmoplegia | Pathogenic | These germline variants are typically inherited in an autosomal dominant pattern with variable penetrance. The clinical phenotype is characterized by: - Generalized muscle weakness and hypotonia presenting in infancy or early childhood - Delayed motor milestones - Facial weakness and ptosis - Respiratory muscle involvement in severe cases - Muscle biopsy showing fiber-type disproportion, nemaline rods, or core-like lesions ### 4.3 MYOD1 in Other Malignancies Beyond RMS, MYOD1 alterations have been reported in other tumor types: **Rhabdoid tumors**: Atypical teratoid/rhabdoid tumors (AT/RT) may express MYOD1 as a marker of rhabdomyoblastic differentiation, but somatic mutations are rare. **Leiomyosarcoma**: MYOD1 expression is occasionally observed in leiomyosarcoma, but mutations are absent. **Desmoplastic small round cell tumor (DSRCT)**: MYOD1 is not typically mutated but may be expressed as part of the myogenic differentiation program. **Breast cancer**: A subset of metaplastic breast carcinomas with rhabdomyosarcomatous differentiation harbor MYOD1 amplification or overexpression, though mutations are rare. ### 4.4 Diagnostic and Prognostic Utility MYOD1 immunohistochemistry is a standard diagnostic tool for RMS. Nuclear MYOD1 expression is observed in >90% of RMS cases, including both alveolar and embryonal subtypes. However, MYOD1 expression is not entirely specific and can be seen in other small round cell tumors, including Ewing sarcoma, neuroblastoma, and lymphoma. Therefore, MYOD1 staining is typically interpreted in conjunction with other markers (desmin, myogenin, MYF5, PAX7). The detection of MYOD1 p.L122R mutation has significant prognostic value. Patients with MYOD1-mutant RMS have a markedly worse prognosis compared to those with wild-type MYOD1, regardless of histologic subtype. Consequently, MYOD1 mutation status is now incorporated into risk stratification algorithms for RMS clinical trials. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Oncoproteins and MYOD1 Several viral oncoproteins interact with MYOD1, either to subvert myogenic differentiation or to promote viral replication: **Adenovirus E1A**: The adenoviral E1A oncoprotein binds to MYOD1 and inhibits its transcriptional activity. E1A disrupts the interaction between MYOD1 and p300/CBP, preventing histone acetylation at MYOD1 target genes. This inhibition of myogenesis is thought to create a cellular environment conducive to viral replication. E1A also promotes the degradation of MYOD1 via the ubiquitin-proteasome pathway. **SV40 Large T antigen**: The SV40 large T antigen binds to MYOD1 and sequesters it in the cytoplasm, preventing nuclear translocation and DNA binding. This interaction is mediated by the T antigen's J-domain, which recruits Hsc70 to unfold MYOD1 and disrupt its nuclear import. **Human papillomavirus (HPV) E7**: The HPV E7 oncoprotein binds to MYOD1 and inhibits its transcriptional activity by recruiting HDAC1 to MYOD1 target gene promoters. E7 also promotes MYOD1 degradation via the ubiquitin-proteasome pathway, contributing to the inhibition of myogenic differentiation in HPV-infected cells. **Epstein-Barr virus (EBV) EBNA2**: EBNA2, a transcriptional activator essential for B-cell transformation, interacts with MYOD1 and modulates its activity. In EBV-infected cells, EBNA2 can activate MYOD1 target genes in a non-muscle context, potentially contributing to the aberrant expression of muscle markers in EBV-associated tumors. ### 5.2 Bacterial Effectors and Toxins **Clostridium botulinum neurotoxin**: While not directly targeting MYOD1, botulinum neurotoxin cleaves SNARE proteins, leading to paralysis. The resulting muscle inactivity leads to downregulation of MYOD1 expression and muscle atrophy. **Staphylococcus aureus α-toxin**: This pore-forming toxin induces myoblast death and downregulates MYOD1 expression, contributing to muscle damage in staphylococcal infections. **Mycobacterium tuberculosis**: Infection of macrophages with M. tuberculosis induces a granulomatous response that can involve muscle tissue. MYOD1 expression is downregulated in infected muscle, contributing to cachexia. ### 5.3 Parasitic Infections **Trypanosoma cruzi** (Chagas disease): The parasite invades cardiac and skeletal muscle cells. Infection leads to downregulation of MYOD1 and impaired muscle regeneration, contributing to the chronic cardiomyopathy characteristic of Chagas disease. **Trichinella spiralis**: This nematode infects skeletal muscle, forming nurse cells. The infection induces a regenerative response characterized by upregulation of MYOD1 and satellite cell activation, but the parasite subverts this response to establish a chronic infection. ### 5.4 Immune Evasion Mechanisms MYOD1 is not a direct target of immune evasion mechanisms, but its expression in rhabdomyosarcoma has implications for tumor immunology. MYOD1-mutant RMS tumors exhibit: - Reduced expression of MHC class I molecules, leading to immune evasion - Increased expression of PD-L1, which inhibits T-cell activation - Recruitment of immunosuppressive myeloid-derived suppressor cells (MDSCs) - Reduced infiltration of cytotoxic T lymphocytes (CTLs) These immune evasion mechanisms contribute to the aggressive clinical behavior of MYOD1-mutant RMS and have implications for immunotherapy approaches. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 MYOD1 as a Therapeutic Target MYOD1 is an attractive therapeutic target in RMS, particularly in the aggressive MYOD1-mutant subtype. However, targeting a transcription factor with small molecules is challenging due to the lack of a well-defined small-molecule binding pocket. Several strategies are being explored: ### 6.2 Small-Molecule Inhibitors **CDK inhibitors**: MYOD1-mutant RMS cells exhibit hyperactivation of CDK2 and CDK4, which phosphorylate and inactivate wild-type MYOD1 but not the L122R mutant. CDK inhibitors such as palbociclib (CDK4/6 inhibitor) and dinaciclib (CDK2 inhibitor) have shown preclinical efficacy in MYOD1-mutant RMS models. Palbociclib is currently being evaluated in clinical trials for RMS (NCT03526250). **HDAC inhibitors**: HDAC inhibitors (e.g., vorinostat, panobinostat) can reactivate MYOD1 target genes by promoting histone acetylation. In MYOD1-mutant RMS, HDAC inhibitors have shown synergistic effects with CDK inhibitors. Vorinostat is being evaluated in combination with chemotherapy for RMS (NCT02389244). **BET inhibitors**: Bromodomain and extraterminal (BET) inhibitors (e.g., JQ1, OTX015) disrupt the interaction between BRD4 and acetylated histones, leading to downregulation of MYOD1 target genes. BET inhibitors have shown efficacy in MYOD1-mutant RMS xenograft models. **Proteasome inhibitors**: Bortezomib and carfilzomib inhibit the proteasome, leading to accumulation of ubiquitinated proteins, including MYOD1. In MYOD1-mutant RMS, proteasome inhibition leads to accumulation of the mutant protein, which may have dominant-negative effects. However, clinical efficacy has been limited. ### 6.3 Investigational Agents Targeting MYOD1 Signaling **IGF1R inhibitors**: The IGF1R/PI3K/AKT pathway is hyperactivated in MYOD1-mutant RMS. IGF1R inhibitors (e.g., linsitinib, ganitumab) have shown preclinical efficacy and are being evaluated in clinical trials (NCT03041701). **mTOR inhibitors**: Everolimus and temsirolimus inhibit mTORC1, which is downstream of PI3K/AKT. These agents have shown modest activity in RMS and are being evaluated in combination with chemotherapy. **MEK inhibitors**: Trametinib and selumetinib inhibit MEK1/2, which is downstream of RAS. These agents have shown activity in RAS-mutant RMS but limited efficacy in MYOD1-mutant tumors. **WNT pathway inhibitors**: Porcupine inhibitors (e.g., WNT974) and tankyrase inhibitors (e.g., XAV939) target the WNT/β-catenin pathway, which is upstream of MYOD1. These agents have shown preclinical efficacy in RMS models. ### 6.4 Gene Therapy and Cell-Based Approaches **CRISPR/Cas9 gene editing**: Correction of the MYOD1 L122R mutation using CRISPR/Cas9 has been demonstrated in preclinical RMS models. This approach restores wild-type MYOD1 function and inhibits tumor growth. However, delivery of CRISPR components to tumor cells in vivo remains a significant challenge. **Oncolytic viruses**: Oncolytic viruses engineered to express MYOD1 or to target MYOD1-expressing cells are being developed. For example, an oncolytic adenovirus expressing a MYOD1-responsive suicide gene has shown efficacy in RMS xenograft models. **CAR-T cell therapy**: Chimeric antigen receptor (CAR) T cells targeting MYOD1-expressing tumor cells are being developed. However, the expression of MYOD1 in normal muscle tissue raises concerns about on-target, off-tumor toxicity. ### 6.5 Pharmacogenomic Considerations The presence of MYOD1 mutations may influence the response to chemotherapy: - **Vincristine**: MYOD1-mutant RMS cells exhibit resistance to vincristine, likely due to upregulation of drug efflux pumps (ABCB1, ABCG2). - **Actinomycin D**: MYOD1-mutant RMS cells are partially resistant to actinomycin D, possibly due to altered DNA repair pathways. - **Cyclophosphamide**: MYOD1-mutant RMS cells are sensitive to cyclophosphamide, but the response is short-lived due to the emergence of resistant clones. - **Irinotecan**: MYOD1-mutant RMS cells exhibit variable sensitivity to irinotecan, with some models showing resistance. These pharmacogenomic differences underscore the need for genotype-guided treatment strategies in RMS. --- ## 7. Bioinformatic Resources & Database Accessions | Database | Accession/ID | URL | |---|---|---| | NCBI Gene | 4654 | https://www.ncbi.nlm.nih.gov/gene/4654 | | Ensembl | ENSG00000129152 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000129152 | | UniProt | P15172 | https://www.uniprot.org/uniprotkb/P15172 | | RCSB PDB | 1MDY, 2QLK | https://www.rcsb.org/structure/1MDY | | HGNC | 7608 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7608 | | OMIM | 159970 | https://www.omim.org/entry/159970 | | ClinVar | Gene: MYOD1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=MYOD1 | | COSMIC | Gene: MYOD1 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MYOD1 | | STRING | P15172 | https://string-db.org/network/P15172 | | BioGRID | 112847 | https://thebiogrid.org/112847 | | Gene Ontology (GO) | GO:0000981, GO:0003700, GO:0005515, GO:0005634, GO:0006357, GO:0006366, GO:0007517, GO:0042692, GO:0045944 | https://www.ebi.ac.uk/QuickGO/ | | Reactome | R-HSA-525793, R-HSA-525794, R-HSA-525795 | https://reactome.org/ | | KEGG | hsa:4654 ## Related Clinical & Scientific Guides * [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway) * [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway) * [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)